KRMD - Repro-Med Systems Inc Stock Price, Fair Value and News

2.28-0.08 (-3.39%)Market Closed

Market Summary

2.28-0.08

Market Closed

-3.39%

KRMD Stock Price

View Fullscreen

KRMD RSI Chart

KRMD Valuation

Market Cap

103.9M

Price/Earnings (Trailing)

-7.83

Price/Sales (Trailing)

3.54

EV/EBITDA

-11.96

Price/Free Cashflow

-179.52

KRMD Price/Sales (Trailing)

KRMD Profitability

EBT Margin

-29.74%

Return on Equity

-69.39%

Return on Assets

-48.24%

Free Cashflow Yield

-0.56%

KRMD Fundamentals

KRMD Revenue

Revenue (TTM)

29.3M

Rev. Growth (Yr)

10.89%

Rev. Growth (Qtr)

14.08%

KRMD Earnings

Earnings (TTM)

-13.3M

Earnings Growth (Yr)

19.7%

Earnings Growth (Qtr)

74.07%

Breaking Down KRMD Revenue

Last 7 days

2.3%

Last 30 days

7.1%

Last 90 days

5.6%

Trailing 12 Months

-40.9%

How does KRMD drawdown profile look like?

KRMD Financial Health

Current Ratio

4.01

KRMD Investor Care

Shares Dilution (1Y)

0.33%

Diluted EPS (TTM)

-0.28

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	29.3M	0	0	0
2023	29.0M	29.4M	28.7M	28.5M
2022	24.3M	25.3M	27.0M	27.9M
2021	23.3M	21.1M	21.1M	23.5M
2020	24.5M	26.9M	26.3M	24.2M
2019	18.3M	19.1M	21.2M	23.2M
2018	16.6M	17.3M	18.0M	17.4M
2017	12.4M	13.5M	14.2M	16.2M
2016	12.2M	12.2M	12.2M	12.4M
2015	11.2M	11.2M	11.9M	12.4M
2014	8.7M	9.5M	10.0M	10.4M
2013	7.8M	7.9M	8.0M	8.1M
2012	6.4M	6.6M	7.2M	7.8M
2011	4.9M	5.3M	5.7M	6.0M
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Repro-Med Systems Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 31, 2024	matin shahriar	acquired	14,999	2.37	6,329	-
Mar 31, 2024	wholihan edward	acquired	14,999	2.37	6,329	-
Mar 31, 2024	cascella robert	acquired	14,999	2.37	6,329	-
Mar 31, 2024	manko joseph m. jr.	acquired	-	-	6,329	-
Mar 31, 2024	fletcher r john	acquired	22,498	2.37	9,493	-
Mar 31, 2024	french donna	acquired	14,999	2.37	6,329	-
Mar 13, 2024	tharby linda m	sold (taxes)	-14,826	2.09	-7,094	president and ceo
Mar 13, 2024	tharby linda m	acquired	41,133	2.09	19,681	president and ceo
Feb 16, 2024	manko joseph m. jr.	sold	-	-	-27,700	-
Jan 10, 2024	manko joseph m. jr.	sold	-	-	-453,231	-

Which funds bought or sold KRMD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	added	1.85	-1,060	49,503	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	sold off	-100	-13,883	-	-%
May 15, 2024	Royal Bank of Canada	reduced	-62.43	-67,000	38,000	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-39.48	-51,516	71,666	-%
May 15, 2024	BARCLAYS PLC	reduced	-47.96	-59,000	59,000	-%
May 15, 2024	Meros Investment Management, LP	added	26.76	282,099	1,572,850	0.70%
May 15, 2024	272 Capital LP	reduced	-9.88	-495,657	1,753,650	0.70%
May 15, 2024	Steward Partners Investment Advisory, LLC	unchanged	-	-78.00	1,935	-%
May 15, 2024	MORGAN STANLEY	added	93.6	159,802	345,381	-%
May 15, 2024	STATE STREET CORP	unchanged	-	-46,256	1,149,100	-%

Are Funds Buying or Selling KRMD?

Are funds buying KRMD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own KRMD

No. of Funds

Unveiling Repro-Med Systems Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	first light asset management, llc	11.30%	5,158,444	SC 13G
Feb 13, 2024	archon capital management llc	8.15%	3,720,876	SC 13G/A
Jan 02, 2024	horton capital partners, llc	16.66%	7,609,751	SC 13D/A
Feb 24, 2023	horton capital partners, llc	16.%	7,430,603	SC 13D/A
Feb 14, 2023	first light asset management, llc	13.91%	6,299,771	SC 13G/A
Feb 13, 2023	archon capital management llc	6.56%	2,969,732	SC 13G/A
Feb 14, 2022	archon capital management llc	6.41%	2,856,502	SC 13G
Feb 14, 2022	first light asset management, llc	13.03%	5,807,647	SC 13G/A
Apr 06, 2021	horton capital partners, llc	16.77%	7,459,776	SC 13D/A
Jan 08, 2021	first light asset management, llc	13.36%	5,871,364	SC 13G/A

Recent SEC filings of Repro-Med Systems Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	8-K	Current Report
May 01, 2024	10-Q	Quarterly Report
May 01, 2024	8-K	Current Report
Apr 11, 2024	8-K	Current Report
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading

Peers (Alternatives to Repro-Med Systems Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.83%	-87.10%	-0.09	0.28	5.77%	8.23%

Repro-Med Systems Inc News

Latest updates

Repro-Med Systems Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	14.1%	8,197,798	7,185,932	7,003,198	6,935,931	7,392,605	7,344,681	7,760,398	6,546,628	6,244,330	6,490,506	6,040,544	5,528,174	5,430,951	4,057,220	6,080,315	7,708,904	6,330,009	6,222,134	6,617,397	5,348,812	4,974,278
Gross Profit	17.8%	5,103,298	4,330,946	4,342,177	3,888,124	4,147,035	4,078,146	4,322,362	3,346,173	3,622,305	3,831,790	3,495,750	3,210,184	3,231,854	2,297,273	3,940,723	4,909,880	3,788,210	3,947,284	4,382,908	3,475,664	3,047,954
Operating Expenses	8.2%	7,064,664	6,528,500	6,133,198	7,112,700	7,203,863	6,589,563	5,851,841	6,959,635	6,748,820	5,944,948	4,817,784	4,591,238	5,445,143	3,461,706	3,581,897	5,941,881	3,205,387	4,106,928	3,558,424	3,439,786	3,162,993
S&GA Expenses	6.9%	5,357,620	5,012,645	4,623,928	5,303,167	5,425,877	4,759,923	4,825,349	5,530,022	5,491,213	4,881,710	3,901,830	4,085,945	4,992,829	2,938,750	3,075,169	3,201,831	2,862,138	2,795,060	2,441,381	2,050,435	2,484,868
R&D Expenses	14.6%	1,475,674	1,287,515	1,293,256	1,596,614	1,564,869	1,641,982	862,148	1,303,731	1,148,355	949,930	800,020	386,878	336,841	352,117	390,416	298,196	256,025	290,021	170,260	178,235	101,959
EBITDA Margin	14.5%	-0.27	-0.31	-0.32	-0.31	-0.34	-0.36	-0.34	-0.36	-0.28	-0.25	-0.15	-0.07	-	-	-	-	-	-	-	-	-
Interest Expenses	-23.4%	12,296	16,059	14,608	7,839	12,326	12,790	9,496	1,779	4,425	7,047	6,147	19.00	28.00	38.00	14,144	13,467	87.00	62.00	47.00	59.00	174
Income Taxes	-100.0%	-	5,445,122	-300,247	-599,995	-577,400	-434,659	-271,500	-710,260	-597,599	-375,837	-238,104	-245,316	-942,361	-334,000	143,353	30,919	141,928	-57,196	186,681	24,683	-22,099
Earnings Before Taxes	4.2%	-1,935,958	-2,020,907	-1,668,509	-3,095,881	-2,988,285	-2,411,386	-1,497,060	-3,631,601	-3,135,113	-1,444,195	-1,331,882	-1,369,865	-2,218,499	1,255,498	392,528	-1,045,119	591,356	-137,453	838,494	102,866	-107,489
EBT Margin	13.2%	-0.30	-0.34	-0.35	-0.34	-0.36	-0.38	-0.36	-0.38	-0.30	-0.27	-0.17	-0.09	-	-	-	-	-	-	-	-	-
Net Income	74.1%	-1,935,958	-7,466,029	-1,368,262	-2,495,886	-2,410,885	-1,976,727	-1,225,560	-2,921,341	-2,537,514	-1,068,358	-1,093,778	-1,124,549	-1,276,138	-834,628	249,175	-1,076,038	449,428	-80,257	651,813	78,183	-85,390
Net Income Margin	6.1%	-0.45	-0.48	-0.29	-0.28	-0.29	-0.31	-0.29	-0.30	-0.24	-0.19	-0.21	-0.14	-	-	-	-	-	-	-	-	-
Free Cashflow	-131.6%	-346,720	1,096,805	-1,269,659	-248,758	-4,755,404	1,241,643	-2,210,520	-2,968,063	-1,846,893	-811,953	-921,049	-265,318	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-3.4%	28.00	28.00	35.00	36.00	38.00	42.00	43.00	42.00	43.00	41.00	41.00	41.00	42.00	40.00	45.00	48.00	17.00	14.00	14.00	12.00	12.00
Current Assets	-3.8%	19.00	20.00	22.00	23.00	25.00	30.00	31.00	31.00	34.00	37.00	38.00	37.00	39.00	38.00	43.00	45.00	14.00	12.00	12.00	10.00	10.00
Cash Equivalents	-5.8%	11.00	11.00	11.00	12.00	12.00	17.00	16.00	18.00	23.00	25.00	26.00	27.00	27.00	27.00	32.00	38.00	7.00	6.00	5.00	4.00	3.00
Inventory	-9.6%	3.00	3.00	5.00	5.00	7.00	6.00	7.00	7.00	6.00	6.00	7.00	8.00	8.00	7.00	6.00	4.00	3.00	2.00	3.00	3.00	3.00
Net PPE	-2.1%	4.00	4.00	4.00	4.00	4.00	4.00	3.00	3.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	3.4%	8.00	8.00	8.00	8.00	8.00	11.00	10.00	10.00	9.00	5.00	5.00	3.00	5.00	4.00	5.00	8.00	4.00	3.00	3.00	2.00	2.00
Current Liabilities	8.9%	5.00	4.00	4.00	4.00	5.00	7.00	6.00	6.00	5.00	5.00	5.00	3.00	5.00	4.00	5.00	8.00	4.00	2.00	2.00	2.00	2.00
Shareholder's Equity	-6.1%	19.00	20.00	27.00	28.00	30.00	31.00	32.00	33.00	35.00	37.00	37.00	37.00	38.00	36.00	40.00	39.00	12.00	11.00	11.00	10.00	9.00
Retained Earnings	-8.3%	-25.25	-23.31	-15.85	-14.48	-11.98	-9.57	-7.59	-6.37	-3.45	-0.91	0.00	1.00	2.00	4.00	4.00	4.00	5.00	5.00	5.00	4.00	4.00
Additional Paid-In Capital	1.5%	48.00	47.00	47.00	46.00	45.00	44.00	43.00	42.00	42.00	41.00	40.00	39.00	39.00	36.00	35.00	35.00	7.00	6.00	6.00	5.00	5.00
Accumulated Depreciation	7.8%	3.00	3.00	-	-	-	3.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	0.1%	46.00	46.00	46.00	46.00	46.00	45.00	45.00	45.00	45.00	45.00	44.00	44.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	111	-	-	-	72.00	-	-	-	120	-	-	-	212	-	-	-	55.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-131.6%	-346	1,097	-1,174	-153	-4,660	1,336	-2,115	-2,873	-1,752	-717	-826	-170	-2,605	-1,711	-1,739	2,554	153	823	982	-438	-1,045
Share Based Compensation	79.8%	700	389	698	801	881	718	782	742	838	740	628	605	734	428	406	424	361	308	368	231	298
Cashflow From Investing	36.1%	-133	-208	-213	-108	-283	-223	-648	-1,176	-752	-47.68	-151	-64.93	-102	-28.61	-494	-333	-180	-79.07	-143	1,629	-96.83
Cashflow From Financing	-2.1%	-182	-178	441	-242	-238	-145	940	-262	-252	-133	673	-813*	2,167	-3,378	-3,462	28,480	1,584	-1.66	483	24.00	-3.85
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.00	-2.82

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

KRMD Income Statement

2024-03-31

STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended
STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
NET REVENUES	$ 8,197,798	$ 7,392,605
Cost of goods sold	3,094,500	3,245,570
Gross Profit	5,103,298	4,147,035
OPERATING EXPENSES
Selling, general and administrative	5,357,620	5,425,877
Research and development	1,475,674	1,564,869
Depreciation and amortization	231,370	213,117
Total Operating Expenses	7,064,664	7,203,863
Net Operating Loss	(1,961,366)	(3,056,828)
Non-Operating Income/(Expense)
Loss on currency exchange	(11,479)	(680)
Loss on disposal of fixed assets, net	(300)	(56,279)
Interest income, net	37,187	125,502
TOTAL OTHER INCOME	25,408	68,543
LOSS BEFORE INCOME TAXES	(1,935,958)	(2,988,285)
Income Tax Benefit		577,400
NET LOSS	$ (1,935,958)	$ (2,410,885)
NET LOSS PER SHARE
Basic	$ (0.04)	$ (0.05)
Diluted	$ (0.04)	$ (0.05)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING
Basic	45,712,224	45,487,593
Diluted	45,712,224	45,487,593

KRMD Balance Sheet

2024-03-31

BALANCE SHEETS (UNAUDITED) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
CURRENT ASSETS
Cash and cash equivalents	$ 10,820,317	$ 11,482,240
Accounts receivable less allowance for doubtful accounts of $24,777 as of March 31, 2024 and $24,777 as of December 31, 2023	4,392,511	4,045,211
Inventory	3,147,312	3,481,301
Other receivables	288,714	28,889
Prepaid expenses	830,408	1,218,288
TOTAL CURRENT ASSETS	19,479,262	20,255,929
Property and equipment, net	3,755,530	3,837,657
Intangible assets, net of accumulated amortization of $406,801 and $390,341 as of March 31, 2024 and December 31, 2023, respectively	737,901	754,361
Operating lease right-of-use assets	3,428,885	3,514,055
Deferred income tax assets, net of allowance for non-realization of deferred tax assets of $6,391,452 and $6,002,777 for March 31, 2024 and December 31, 2023, respectively
Other assets	98,970	98,970
TOTAL ASSETS	27,500,548	28,460,972
CURRENT LIABILITIES
Accounts payable	1,774,185	975,193
Accrued expenses	1,459,405	1,711,427
Note payable	159,031	314,344
Other liabilities	457,653	512,520
Accrued payroll and related taxes	519,441	462,941
Financing lease liability – current	111,103	109,540
Operating lease liability – current	372,109	368,313
TOTAL CURRENT LIABILITIES	4,852,927	4,454,278
Financing lease liability, net of current portion	288,253	316,623
Operating lease liability, net of current portion	3,241,837	3,336,300
TOTAL LIABILITIES	8,383,017	8,107,201
STOCKHOLDERS’ EQUITY
Common stock, $0.01 par value, 75,000,000 shares authorized, 49,143,589 and 49,089,864 shares issued 45,723,087 and 45,669,362 shares outstanding as of March 31, 2024, and December 31, 2023, respectively	491,436	490,899
Additional paid-in capital	47,717,888	47,018,707
Treasury stock, 3,420,502 shares as of March 31, 2024 and December 31, 2023, at cost	(3,843,562)	(3,843,562)
Accumulated deficit	(25,248,231)	(23,312,273)
TOTAL STOCKHOLDERS’ EQUITY	19,117,531	20,353,771
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 27,500,548	$ 28,460,972

About Repro-Med Systems Inc

KORU Medical Systems, Inc. designs, manufactures, and markets portable medical devices primarily for the subcutaneous drug delivery market in the United States and internationally. It offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company also provides education and training materials to clinicians, patients, and patient advocates. It sells its products through direct sales and medical device distributors, as well as online. The company was incorporated in 1980 and is headquartered in Mahwah, New Jersey.

CEO	Ms. Linda M. Tharby
WEBSITE	korumedical.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	85

Repro-Med Systems Inc Frequently Asked Questions

What is the ticker symbol for Repro-Med Systems Inc? What does KRMD stand for in stocks?

KRMD is the stock ticker symbol of Repro-Med Systems Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Repro-Med Systems Inc (KRMD)?

As of Fri May 17 2024, market cap of Repro-Med Systems Inc is 103.88 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KRMD stock?

You can check KRMD's fair value in chart for subscribers.

What is the fair value of KRMD stock?

You can check KRMD's fair value in chart for subscribers. The fair value of Repro-Med Systems Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Repro-Med Systems Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for KRMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Repro-Med Systems Inc a good stock to buy?

The fair value guage provides a quick view whether KRMD is over valued or under valued. Whether Repro-Med Systems Inc is cheap or expensive depends on the assumptions which impact Repro-Med Systems Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KRMD.

What is Repro-Med Systems Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, KRMD's PE ratio (Price to Earnings) is -7.83 and Price to Sales (PS) ratio is 3.54. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KRMD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Repro-Med Systems Inc's stock?

In the past 10 years, Repro-Med Systems Inc has provided 0.251 (multiply by 100 for percentage) rate of return.